Despite considerable therapeutic advances, heart failure remains a medical and
socioeconomic problem. Thus, there is a compelling need for new drugs that could improve …

Chronic heart failure is one of the leading causes for hospitalization in the United States and
Europe, and is accompanied by high mortality. Current pharmacological therapy of chronic …

Although there have been significant advances in the therapy of heart failure in recent
decades, such as the introduction of beta-blockers and antagonists of the renin–angiotensin …

Introduction/background: Heart failure is a major cause of cardiovascular morbidity and
mortality. This review covers current heart failure treatment guidelines, emerging therapies …

Despite past advances in the pharmacological management of heart failure, the prognosis of
these patients remains poor, and for many, treatment options remain unsatisfactory …

Despite> 100 clinical trials, only 2 new drugs had been approved by the US Food and Drug
Administration for the treatment of chronic heart failure in more than a decade: the …

Abstract Background Heart Failure continues to be a leading cause of mortality and
morbidity worldwide. The dismal prognosis of patients in acute heart failure (AHF) can be …

Understanding of contemporary pharmacological therapy for chronic heart failure continues
to evolve. In this Review, we discuss how findings from clinical trials have caused the roles …

The incidence of heart failure is primarily flat or declining for a presumably reflecting better
management of cardiovascular diseases, but that of heart failure with preserved ejection …

Heart failure is a substantial and escalating global health challenge, affecting millions
worldwide. This complex syndrome arises from diverse etiologies, encompassing ischemic …